Haleon

Alliance Pharmaceuticals Limited is a UK-based international consumer healthcare company founded in 1996 and incorporated in 2001. The company specializes in acquiring, marketing, and selling pharmaceutical and consumer health products in over 100 countries. With around 290 employees, its headquarters is located in Chippenham, Wiltshire. Alliance has evolved from niche prescription medicines to a significant player in the consumer healthcare sector, utilizing an asset-light model that focuses on marketing and partnerships. The company operates through a global marketing strategy, leveraging distributor networks and e-commerce platforms like Tmall, JD.com, and Amazon. Alliance emphasizes insight-led campaigns and brand protection while managing a diverse portfolio of products. Notable brands include KELO-COTE™, an advanced silicone treatment for scars, Nizoral™, an anti-dandruff shampoo, and ScarAway®, a silicone-based scar treatment acquired in 2022. Alliance Pharmaceuticals continues to expand its reach and capabilities, with reported revenue around $230.2 million.

Halcyon Biotechnologies is a company developing cognitive enhancement therapeutics.

Lonza Group AG is a Swiss multinational manufacturing company based in Basel, specializing in contract development and manufacturing services for the pharmaceutical, biotechnology, and nutrition sectors. Founded in 1897, Lonza has evolved from its origins in hydroelectric power to become a leader in biopharmaceutical manufacturing, operating over thirty development and manufacturing sites worldwide. As a pure-play contract development and manufacturing organization (CDMO), Lonza offers a wide range of services, including biologics manufacturing, small molecules production, bioconjugates, and cell and gene therapies. The company also provides drug product services and detection systems for the bioscience sector. Lonza has established significant partnerships with major pharmaceutical companies, including a notable collaboration with Moderna for the production of its COVID-19 vaccine. With a strong market position, Lonza plays a crucial role in the growth of outsourced drug manufacturing and the development of innovative therapies.